Compare ADMA Biologics Inc (ADMA) vs BlackRock TCP Capital Corp (TCPC) Price & Performance

ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.

The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.

TCPC trades at $3.25, down 3.27% on the day, with a bearish technical outlook and negative revenue trends. The stock shows a low price-to-book ratio of 0.48 but faces challenges with negative net income and declining profitability. Recent news highlights a shareholder investigation into fiduciary duties, adding to investor concerns amid mixed analyst sentiment.

The outlook remains cautious due to persistent losses and legal scrutiny. Opportunities exist from the discounted book value and dividend yield, but risks from earnings misses and negative cash flow outweigh near-term upside potential.